Thyroid papillary cancers (PTCs) are associated with activating mutations of genes coding
for RET or TRK tyrosine kinase receptors, as well as of RAS genes. Activating mutations of …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

Abstract The RAS-RAF-MEK-ERK-MAP kinase pathway mediates the cellular response to
extracellular signals that regulate cell proliferation, differentiation, and apoptosis. Mutation of …

Activating mutations of BRAF have been identified in a variety of human cancers, most
notably melanomas and papillary thyroid carcinomas (PTCs). The aim of the present study …

Objectives The genes RET and RAS, and more recently BRAF, have been shown to be
frequently mutated in human papillary thyroid carcinomas (PTC). The aim of this study was …

Rearrangement of RET proto-oncogene is the major event in the etiopathogenesis of
papillary thyroid carcinoma (PTC). We report a high prevalence of BRAF V599E mutation in …

Thyroid papillary carcinoma is the most common type of endocrine cancer. It is frequently
associated with genetic alterations leading to activation of the MAPK signaling pathway. The …

Mortality is low for young patients (younger than 21 years) with papillary thyroid cancer
(PTC), and different mutations might contribute to this. Previous studies detected ret/PTC …

Summary Purpose BRAF V600E mutation represents the most common oncogenic event in
sporadic papillary thyroid cancer (PTC). There are, however, significant discrepancies …

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …